TB-500 mechanism, half-life, primary literature on thymosin beta-4 and the TB-500 fragment. Research-grade reference for serious operators.
A synthetic peptide based on an active region of thymosin beta-4, sold for research use only and most often paired with BPC-157 in what the founder-biohacker community calls the Wolverine stack.
TB-500 is the common shorthand for a synthetic peptide derived from thymosin beta-4, often abbreviated TB-4. Thymosin beta-4 is a 43-amino-acid actin-binding protein expressed in nearly every cell type in the body. The TB-500 research fragment is shorter than the parent protein. The exact sequence vendors ship varies. This is the first thing operators get wrong about this compound, and it matters.
The biology of thymosin beta-4 was characterized by Allan Goldstein and his collaborators beginning in the 1980s, building on earlier thymic-fraction work. Goldstein's group founded RegeneRx, which ran a series of clinical trials on the parent TB-4 protein for indications including dry eye, corneal wounds, and cardiac repair. Those trials studied TB-4. They did not study TB-500. The distinction matters because most of the marketing collapses the two and the literature does not.
In commercial markets the compound is sold RUO — research use only. It is not approved as a drug in the United States or the European Union for any indication. None of that has stopped the founder-biohacker community from running it, generally alongside BPC-157, in the same recovery and soft-tissue context. It is the math operators are choosing to do under their own labs, with their own physician relationships, eyes open.
This page is mechanism, half-life, and where the literature lives — not bro-science.
Thymosin beta-4 binds G-actin — the monomer form of the cytoskeletal protein actin — with high affinity. By sequestering G-actin, TB-4 modulates the polymerization equilibrium between G-actin and F-actin, the filamentous form that gives cells structure and the ability to migrate. That is the molecular root.
Downstream, the published work on TB-4 documents:
Cell migration. TB-4 promotes the migration of endothelial cells, keratinocytes, and progenitor cells into wound beds. This is the cleanest mechanism in the corpus and the basis for the dry-eye and corneal-wound trials.
Angiogenesis. TB-4 upregulates pro-angiogenic signaling, with downstream capillary ingrowth at sites of injury. Cardiac repair models in mice are the most-cited.
Anti-inflammatory and anti-apoptotic effects. TB-4 modulates cytokine signaling and reduces apoptosis in cardiac and neuronal tissue under ischemic stress in animal models.
The TB-500 research fragment is intended to capture the migration-and-repair signaling of the parent protein in a smaller, easier-to-synthesize molecule. Whether the fragment fully recapitulates the activity of the full 43-residue protein in humans is not well-characterized. That is a real gap.
The honest summary: TB-4 is a real molecule with a defined mechanism and a real if narrow human trial record. TB-500, the research fragment most operators are buying, is closer in regulatory and evidence terms to BPC-157 than to a drug-development asset.
The literature reports TB-4 plasma half-life in the multi-day range in some pharmacokinetic work, though estimates vary by model and assay. The TB-500 research fragment's exact half-life in humans is not cleanly characterized in published literature. Animal work suggests a shorter window than the parent protein.
Subcutaneous injection is the dominant administered route in research contexts. Intramuscular injection appears in some preclinical work. Oral and topical preparations exist in community circles; the published support for those routes is thin.
Frequency of administration in published research clusters at less-than-daily — twice weekly is common in animal protocols. Operators in the field generally report once- to twice-weekly subcutaneous use, mirroring the research cadence.
Read this section twice.
Tier 1 — Randomized controlled trials in humans. A handful of small-to-mid-size RCTs exist on the parent TB-4 protein for ophthalmic indications, run by RegeneRx and collaborators. Topline reads have been mixed. The TB-500 research fragment that vendors sell has zero published Phase 2 or Phase 3 RCTs in humans.
Tier 2 — Open-label or single-arm human work. Limited. Mostly extensions of the RegeneRx ophthalmic program on parent TB-4. Not a TB-500-fragment corpus.
Tier 3 — Animal and mechanistic. Substantial. Goldstein and collaborators on TB-4 biology spanning four decades. Cardiac repair models post-myocardial-infarction. Wound healing models — full-thickness skin, corneal abrasion, tendon. Neuroprotection models in stroke. Search "thymosin beta-4 wound healing" and "thymosin beta-4 cardiac" on PubMed and the substantive corpus is there.
Tier 4 — Operator n=1. Substantial in volume, noisy in signal. Soft-tissue and joint reports dominate. Slower onset than BPC-157 is the most consistent observation.
The literature is mostly preclinical for the fragment operators are actually buying. The marketing is not. That gap is the thing this page exists to make legible.
TB-500 is most often stacked with BPC-157 for soft-tissue and joint complaints. The community framing — not literature framing — is that BPC-157 acts more locally and TB-500 acts more systemically. The literature does not cleanly support that division. It is a useful operator heuristic, not a published mechanism.
Reported subjective effects build slower than BPC-157. Operators commonly describe four-to-eight-week timelines before noticing a change, versus two-to-four weeks for BPC-157. This is community signal, not trial data.
PIP — post-injection pain — is generally rated low to moderate. The peptide reconstitutes cleanly in bacteriostatic water. Some operators report mild lethargy in the first week of administration; others report nothing.
For chronic, systemic, multi-site soft-tissue complaints — the operator with three nagging joints, a cranky shoulder, and a history of overuse — TB-500 is the more frequently mentioned of the two compounds. For acute, single-site injury, BPC-157 is more frequently mentioned. This is community framing summarized neutrally. It is not endorsement.
Whether the fragment behaves like the parent protein. This is the central unknown. The published trial corpus is on TB-4, not TB-500. Whether the fragment recapitulates the parent's activity in humans at vendor-supplied doses is not well-characterized.
Long-term human safety. Unstudied. The TB-4 trial corpus is short-duration. Chronic operator use over years is not in the literature.
Pro-angiogenic interaction with occult tumors. Same theoretical concern as BPC-157. A pro-angiogenic compound in someone with an undiagnosed solid tumor is a real open question that has not been ruled in or out.
Dose-response. Community dosing varies widely. The literature does not arbitrate, especially for the fragment versus the full protein.
Sequence and purity drift across vendors. Because TB-500 is not a strictly defined molecule the way a drug substance is, sequence and purity drift across the market is a real concern. This is what COAs exist to address.
TB-500 is the systemic complement to BPC-157 in most operator stacks in this cohort. The full peptide map sits in Issue 1: The 2026 Peptide Stack Map — fourteen compounds, mechanism through literature, one page each. Issue 5 goes deeper on the soft-tissue stack and how operators sequence BPC-157 with TB-500 and GHK-Cu.
If recovery and injury are why you are reading this page, the lead magnet to pull is the Wolverine Recovery Stack PDF — BPC-157, TB-500, GHK-Cu, mechanism through literature, in one document, free.
Adjacent compounds on this site: BPC-157 and GHK-Cu.
Three compounds. One reference document. Mechanism, half-life, primary literature, and where the corpus thins.
Subscribe to The Compound at https://www.thecompoundbrief.com/subscribe and the PDF lands in your inbox.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full disclosure on the About page.
BPC-157, TB-500, and the recovery lane — what the literature actually shows.
Download the PDF →